MARK 1A Series: Percutaneous Microwave Ablation for Patients With Lung Tumor(s)

Lung Cancer Clinical Trial

— MARK 1A  

Official title:

MARK 1A Series: Percutaneous Microwave Ablation for Patients With Lung Tumor(s)

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT02673021
• Other study ID #: 15-001758
• Secondary ID: NCI-2022-10762
• Status: Terminated
• Phase: N/A
• Start date: June 8, 2016
• Est. completion date: March 13, 2020

Study information

• Verified date: October 2023
• Source: Mayo Clinic
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Does lung ablation improve clinical outcomes for patients deemed to be surgically high-risk?

Description:

Surgical resection is the gold standard treatment for localized non-small cell lung cancer (NSCLC). However, surgery is invasive and not all patients are surgical candidates, thus providing an opportunity for percutaneous microwave ablation, for both primary and metastatic disease. Patients that are deemed inoperable are typically treated with other targeted therapies such as radiofrequency ablation (RFA), cryoablation and stereotactic body radiation therapy (SBRT), or systemic therapies. Percutaneous microwave ablation (MWA) is an alternative option for targeted treatment of cancer. Microwave tumor ablation is a procedure that uses heat made by an electric current to destroy a tumor (ablation). With imaging equipment, such as ultrasound or CT (computed tomography), and a small incision made in the skin, the tumor is located and treated with radiofrequency energy. The cells that are killed by the microwave ablation are typically not removed but are eventually replaced by fibrosis and scar tissue. Patients will be followed for 1 year by contrast enhanced chest CT, chest PET/CT and chest PET/MRI to evaluate lesion outcomes.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 9
• Est. completion date: March 13, 2020
• Est. primary completion date: March 13, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Subject must be at least 18 years old.

• Subject is able to understand the study procedures and provide informed consent.

• Subject is willing and able to complete the entire study as specified in the protocol, including the follow-up visits.

• Subject has lung lesion that is biopsy-proven cancer (of any type) or suspicious, with confirmation at the time of the procedure.

• Lung lesion(s) are reachable/treatable per clinician opinion.

• Subject can have other location of disease if it is controlled, or there are plans for control.

• Subject has 1 or more lung nodules (not more than 10), that have a mean diameter <3 cm on axial CT scan.

• Life expectancy =6 months

Exclusion Criteria:

• Subject is pregnant or breast feeding.

• Subject has a significant clinical disease or condition, e.g. cardiovascular, respiratory, gastrointestinal, renal, hepatic, hematological, psychiatric or neurologic that would preclude enrollment, as determined by the primary investigator.

• Subject has another location of disease that is not controlled, and there are no plans for control.

• Subject has more than 10 lung nodules.

Related Conditions & MeSH terms

• Cancer of Lung
• Cancer of the Lung
• Lung Cancer
• Lung Neoplasms
• Metastatic Cancer to the Lung
• Neoplasms
• Neoplasms, Lung
• Neoplasms, Pulmonary
• Pulmonary Cancer
• Pulmonary Neoplasms

Intervention

Procedure:
• Microwave ablation
Microwave tumor ablation is a procedure that uses heat made by an electric current to destroy a tumor (ablation). With imaging equipment, such as ultrasound or CT (computed tomography), and a small incision made in the skin, the tumor is located and treated with radiofrequency energy. The cells that are killed by the microwave ablation are typically not removed but are eventually replaced by fibrosis and scar tissue.

Locations

Country	Name	City	State
United States	Mayo Clinic	Rochester	Minnesota
United States	Mayo Clinic in Rochester	Rochester	Minnesota

Sponsors (2)

Lead Sponsor	Collaborator
Mayo Clinic	Medtronic - MITG

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Efficacy of microwave ablation.	Efficacy is defined as achieving the technical success = complete ablation = achieving ablation zone size predicted/necessary for treatment.	3 months
Primary	Assessment of patient adverse events as defined by CTCAE.	The safety evaluation is based on the major complication rates of performing microwave ablation. The intent is to determine if the results are within acceptable range of what is reported for RFA, cryoablation and surgery. If the microwave ablation has a safety profile that is outside the "standard of care" range, then the procedure would be deemed unacceptable and no further studies of the current generation of microwave ablation would be recommended. The study team has deemed major complication rates of 50% or greater as outside of the "standard of care" range.	3 months
Secondary	Pathological response in patients receiving microwave ablation.	Clinical samples and imaging will be examined to determine pathological response.	1 year

External Links

•   Mayo Clinic Clinical Trials